FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments

 FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments

Shots:

  • The US FDA has launched Coronavirus Treatment Acceleration Program (CTAP) to expedite the development of safe and effective drugs targeting COVID-19. FDA’s CTAP is a tool to bring new therapies to the patients as soon as possible
  • Under CTAP, FDA is redeploying staff and streamlining processes to hasten the reviews of clinical trial protocols and single-patient expanded-access requests
  • FDA unveiled that 10 therapeutic agents are in active trials and 15 agents in the planning stages. The FDA highlights some treatments that are currently being investigated for COVID-19 including Gilead’s remdesivir, Roche’s Actemra (tocilizumab) and Sanofi & Regeneron’s Kevzara (sarilumab)

Source 1, Source 2 ­to­ read full press release/ article | Ref: Eyewire, FDA | Image: FDA

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post